FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $25.07, for a total transaction of $968,604.52. Following the transaction, the chief executive officer now owns 3,353,983 shares in the company, valued at $84,084,353.81. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of FibroGen Inc (NASDAQ:FGEN) opened at 25.10 on Tuesday. FibroGen Inc has a 52-week low of $14.50 and a 52-week high of $27.30. The firm’s 50 day moving average is $24.44 and its 200 day moving average is $21.59. The stock’s market capitalization is $1.60 billion.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.01. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Equities analysts expect that FibroGen Inc will post ($2.05) earnings per share for the current year.
var userip;Your IP Address: document.write(userip);
Hedge funds have recently modified their holdings of the stock. BlackRock Fund Advisors increased its stake in shares of FibroGen by 5.7% in the third quarter. BlackRock Fund Advisors now owns 2,170,992 shares of the biopharmaceutical company’s stock valued at $44,940,000 after buying an additional 117,858 shares during the period. FMR LLC increased its stake in shares of FibroGen by 72.5% in the fourth quarter. FMR LLC now owns 1,533,431 shares of the biopharmaceutical company’s stock valued at $32,815,000 after buying an additional 644,528 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of FibroGen by 12.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,449,431 shares of the biopharmaceutical company’s stock valued at $30,003,000 after buying an additional 162,548 shares during the period. State Street Corp increased its stake in shares of FibroGen by 4.8% in the fourth quarter. State Street Corp now owns 1,363,658 shares of the biopharmaceutical company’s stock valued at $29,190,000 after buying an additional 62,438 shares during the period. Finally, Hillhouse Capital Management Ltd. purchased a new stake in shares of FibroGen during the third quarter valued at about $10,612,000. Hedge funds and other institutional investors own 47.74% of the company’s stock.
Several analysts have commented on FGEN shares. Royal Bank of Canada reissued a “buy” rating on shares of FibroGen in a research report on Wednesday, January 18th. Stifel Nicolaus reissued a “positive” rating and set a $33.00 price target on shares of FibroGen in a research report on Wednesday, January 18th. Finally, Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 13th. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $37.50.
FibroGen Company Profile
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.